Lung Cancer最新文献

{"title":"Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies","authors":"Hironori Satoh ,&nbsp;Yusuke Okuma ,&nbsp;Yuki Shinno ,&nbsp;Ken Masuda ,&nbsp;Yuji Matsumoto ,&nbsp;Tatsuya Yoshida ,&nbsp;Yasushi Goto ,&nbsp;Hidehito Horinouchi ,&nbsp;Noboru Yamamoto ,&nbsp;Yuichiro Ohe","doi":"10.1016/j.lungcan.2025.108453","DOIUrl":"10.1016/j.lungcan.2025.108453","url":null,"abstract":"<div><h3>Background</h3><div>Advancements in pharmacotherapy, including molecular targeted therapies and immune checkpoint inhibitors, have revolutionized the treatment for Stage IV non-small cell lung cancer (NSCLC) over the past two decades. However, differences in drug approval timelines across countries raise important questions about their impact on survival rates. This study investigates trends in overall survival (OS), patient characteristics, and the association between OS improvements and the introduction of new drugs.</div></div><div><h3>Patients and methods</h3><div>This retrospective review included patients with Stage IV NSCLC treated at the National Cancer Center Hospital in Japan from 2001 to 2021. Using data from the Department of Thoracic Oncology registries, 2,555 patients were identified and categorized into four time periods: 2001–2005 (Group A), 2006–2010 (Group B), 2011–2015 (Group C), and 2016–2021 (Group D).</div></div><div><h3>Results</h3><div>While baseline characteristics remained relatively consistent, Group D had an increased proportion of elderly patients (≥ 75 years) and those with brain metastases. Additionally, the gender ratio became more balanced over time. Notably, Group D patients with <em>EGFR</em> mutations or <em>ALK</em> fusion positivity and older age demonstrated significantly longer OS. Analysis revealed steady and substantial improvements in OS across time periods (median OS: Group A, 10.68 months; Group B, 14.12 months; Group C, 16.49 months; and Group D, 25.46 months, <strong>respectively</strong>).</div></div><div><h3>Conclusions</h3><div>This study demonstrates marked improvements in survival for patients with Stage IV NSCLC, particularly in the last six years, despite the increase in brain metastases and elderly patients. This finding suggests the crucial role of novel therapies in enhancing survival outcomes.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108453"},"PeriodicalIF":4.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143507978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data","authors":"Molin Zhang ,&nbsp;Chaoqiang Deng ,&nbsp;Fangqiu Fu ,&nbsp;Yuan Li ,&nbsp;Yang Zhang ,&nbsp;Haiquan Chen","doi":"10.1016/j.lungcan.2025.108451","DOIUrl":"10.1016/j.lungcan.2025.108451","url":null,"abstract":"<div><h3>Objectives</h3><div>There is currently no consensus regarding the optimal site-specific postoperative follow-up duration for patients with completely resected non-small cell lung cancer. Long-term surveillance for recurrence may lead to psychological distress or economic burdens for patients.We aimed to propose an appropriate site-specific follow-up strategy for patients with non-small cell lung cancer based on 10-year follow-up data.</div></div><div><h3>Materials and methods</h3><div>We analyzed recurrence patterns in 2,359 patients with non-small cell lung cancer who underwent surgical resection from 2008 to 2013. We established potential site-specific follow-up endpoints when the subsequent recurrence rates fell below 5% and proposed a corresponding follow-up strategy.</div></div><div><h3>Results</h3><div>With a median follow-up of 111.0 months, postoperative recurrences were observed in 985 patients (41.8 %). We identified several factors associated with site-specific recurrence recurrence patterns, including ground-glass opacity component, sex, histology type, and pathological TNM stage. No recurrence was observed in patients with pure ground-glass nodules, a consolidation-to-tumor ratio less than 0.5, or a pathological type classified as lepidic pattern-predominant adenocarcinoma. In thorax, brain and bone, patients with non-squamous cell carcinoma exhibited higher recurrence rates than those with squamous cell carcinoma. In abdomen and neck, male patients have a higher recurrence rate than female patients, particularly within the pathological stage III group.</div></div><div><h3>Conclusions</h3><div>The follow-up strategy was developed based on the recurrence patterns analyzed from ten-year follow-up data. The online tool may assist in determining the optimal site-specific duration for surveillance based on clinicopathologic features.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108451"},"PeriodicalIF":4.5,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143454009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma","authors":"Wonyoung Choi ,&nbsp;Wonyeop Lee ,&nbsp;Youngwook Kim ,&nbsp;Sang-Jin Lee ,&nbsp;Geon Kook Lee ,&nbsp;Seung-Jin Park ,&nbsp;Sinyeong Ju ,&nbsp;Seon-Young Kim ,&nbsp;Cheolju Lee ,&nbsp;Ji-Youn Han","doi":"10.1016/j.lungcan.2025.108448","DOIUrl":"10.1016/j.lungcan.2025.108448","url":null,"abstract":"<div><h3>Background</h3><div>Never-smoker lung adenocarcinoma (NSLA) exhibits distinct immunosuppressive profiles and a lower tumor mutation burden compared with lung adenocarcinoma in smokers. These correlate with poor responses to immune checkpoint inhibitors. In this study, we aimed to elucidate the tumor-immune microenvironment of NSLA without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations and identify novel therapeutic targets.</div></div><div><h3>Methods</h3><div>We analyzed genome, transcriptome, and proteomic data from 102 NSLA tumor samples and 16 normal adjacent tissues. We classified tumors into distinct immune clusters (IC) based on gene signatures by profiling the tumor-infiltrating immune cells.</div></div><div><h3>Results</h3><div>The tumors were stratified into three ICs: hot, intermediate, and cold. Notably, only 21 (20.6%) patients exhibited hot IC enriched in cytotoxic T cells, natural killer cells, and B-cell signatures, which correlated with improved recurrence-free survival. Cold ICs (37.3%) exhibited higher myeloid-derived suppressor cell (MDSC) levels and M2 macrophage signatures, with poor immune cell infiltration and relatively low stimulatory cytokines and chemokines expression. CEACAM1, and NECTIN2 were upregulated in intermediate and cold ICs and correlated with MDSC and M2 macrophage infiltration. High expression of these genes was associated with poor survival outcomes. Protein-protein network analysis of 20 upregulated molecules associated with cancer- and driver-related proteins in cold IC identified XPO 1 as a key component.</div></div><div><h3>Conclusion</h3><div>Our proteogenomic analysis highlighted the immunosuppressive properties of NSLA without EGFR and ALK alterations and identified novel therapeutic targets. These findings may provide novel treatment strategies that could improve the clinical outcomes of patients with NSLA.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108448"},"PeriodicalIF":4.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer","authors":"Kamya Sankar ,&nbsp;Jacob Mercer ,&nbsp;Ellen B. Jaeger ,&nbsp;Jen Godden ,&nbsp;Edward Williams ,&nbsp;Michael A. Thompson ,&nbsp;Shetal A. Patel ,&nbsp;Jane C. Figueiredo ,&nbsp;Frank Weinberg ,&nbsp;Karen L. Reckamp","doi":"10.1016/j.lungcan.2025.108444","DOIUrl":"10.1016/j.lungcan.2025.108444","url":null,"abstract":"<div><h3>Purpose</h3><div>DNA damage response and repair (DDR) gene alterations contribute to genomic instability and increased tumor immunogenicity, yet their clinical significance in non-small cell lung cancer (NSCLC) remains unclear. Using a large real-world dataset, we evaluated the prevalence of DDR alterations and their relation to the tumor immune microenvironment in metastatic NSCLC.</div></div><div><h3>Experimental design</h3><div>We retrospectively analyzed real-world data from patients with metastatic NSCLC using the Tempus AI database. Tumors were sequenced with Tempus xT DNA and xR RNA assays and classified based on the presence (DDRmt) or absence (DDRwt) of a pathogenic somatic alteration or copy number deletion in a DDR pathway gene. Associations between DDR alterations and immune cell infiltration, PD-L1 immunohistochemistry, tumor mutational burden (TMB), and microsatellite instability (MSI-H) were examined.</div></div><div><h3>Results</h3><div>Among 14,127 patients (median age = 67, 49% female), 5,276 (37%) were DDRmt. There was a higher prevalence of current/former smokers in the DDRmt group (86% vs. 82%; p&lt;0.001). DDRmt tumors were more likely to have higher levels of TMB (median: 5.4 vs. 4.6; p&lt;0.001), MSI-H (1.1 % vs. &lt;0.1 %; p&lt;0.001), and infiltrating CD8⁺ T cells (p=0.003) compared to DDRwt tumors. A lower frequency of macrophages (p&lt;0.001) were observed among DDRmt compared with DDRwt tumors with no difference in PDL1 positivity.</div></div><div><h3>Conclusions</h3><div>Among patients with metastatic NSCLC, 37% present with DDRmt tumors characterized by higher TMB, frequency of MSI-H, and changes in immune cell infiltrates. These findings provide insight into the immunogenic landscape of DDR-altered NSCLC and may inform biomarker selection and therapeutic strategies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108444"},"PeriodicalIF":4.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study","authors":"Kenji Morimoto ,&nbsp;Tadaaki Yamada ,&nbsp;Naoki Furuya ,&nbsp;Hisashi Tanaka ,&nbsp;Akihiro Yoshimura ,&nbsp;Tomohiro Oba ,&nbsp;Makoto Hibino ,&nbsp;Takahito Fukuda ,&nbsp;Yasuhiro Goto ,&nbsp;Akira Nakao ,&nbsp;Shinsuke Ogusu ,&nbsp;Yuta Okazaki ,&nbsp;Taishi Harada ,&nbsp;Takayo Ota ,&nbsp;Ken Masubuchi ,&nbsp;Koji Mikami ,&nbsp;Tae Hata ,&nbsp;Shoki Matsumoto ,&nbsp;Ryoichi Honda ,&nbsp;Koji Date ,&nbsp;Koichi Takayama","doi":"10.1016/j.lungcan.2025.108447","DOIUrl":"10.1016/j.lungcan.2025.108447","url":null,"abstract":"<div><h3>Objectives</h3><div>In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (<em>EGFR</em>) mutations, a chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has shown promising outcomes following treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, evidence on whether ABCP provides a survival advantage over platinum-based chemotherapy in real-world clinical settings remains limited. This study aimed to investigate the efficacy and safety of ABCP versus platinum-based chemotherapy in patients with <em>EGFR-</em>mutant NSCLC who underwent EGFR-TKI treatment.</div></div><div><h3>Materials and methods</h3><div>We retrospectively assessed consecutive patients with <em>EGFR-</em>mutant-NSCLC who received platinum-based chemotherapy or ABCP after EGFR-TKI treatment at 20 institutions in Japan between January 2017 and July 2022.</div></div><div><h3>Results</h3><div>Overall, 408 patients with advanced or recurrent <em>EGFR</em>-mutant NSCLC were analyzed. A total of 306 patients (75.0 %) received chemotherapy (Chemo) or chemotherapy plus bevacizumab (Chemo + BEV), and 102 patients (25.0 %) received ABCP. After propensity score matching, no significant differences were noted in progression-free survival (PFS) and overall survival (OS) between the Chemo or Chemo + BEV and ABCP groups (6.0 months versus 7.2 months, log-rank test; p = 0.44 and 22.5 months versus 21.3 months, p = 0.84, respectively). Limiting to the programmed cell death-ligand 1 (PD-L1) ≥ 50 % cohort, the ABCP group had a significantly longer PFS than did the Chemo or Chemo + BEV group (7.9 months versus 4.8 months, log-rank test; p = 0.02).</div></div><div><h3>Conclusion</h3><div>In patients with <em>EGFR</em>-mutant NSCLC previously treated with EGFR-TKI, ABCP achieved comparable outcomes to those of platinum-based chemotherapy. Among patients with high PD-L1 expression, ABCP may be a superior treatment option.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108447"},"PeriodicalIF":4.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two patients suffering from NSCLC with a novel rearrangement mutation in RET (exon2-11del) and their response to pralsetinib as salvage treatment","authors":"Zhen-Jie Huang ,&nbsp;Sha Zhao ,&nbsp;Bi-Lin Lin ,&nbsp;Xin-Yi Ma ,&nbsp;Long Huang","doi":"10.1016/j.lungcan.2025.108446","DOIUrl":"10.1016/j.lungcan.2025.108446","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108446"},"PeriodicalIF":4.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143454011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations","authors":"Adel Shahnam ,&nbsp;Alexander Davis ,&nbsp;Lauren Julia Brown ,&nbsp;Isaac Sullivan ,&nbsp;Kevin Lin ,&nbsp;Chien Ng ,&nbsp;Nicholas Yeo ,&nbsp;Benjamin Y. Kong ,&nbsp;Trisha Khoo ,&nbsp;Lydia Warburton ,&nbsp;Inês Pires Da Silva ,&nbsp;William Mullally ,&nbsp;Wen Xu ,&nbsp;Ken O’Byrne ,&nbsp;Victoria Bray ,&nbsp;Abhijit Pal ,&nbsp;Antony Mersaides ,&nbsp;Malinda Itchins ,&nbsp;Surein Arulananda ,&nbsp;Adnan Nagrial ,&nbsp;Thomas John","doi":"10.1016/j.lungcan.2025.108421","DOIUrl":"10.1016/j.lungcan.2025.108421","url":null,"abstract":"<div><h3>Background</h3><div><em>KRAS G12D</em> and <em>G12C</em> mutations have distinct biological traits influencing treatment response. This study examines real-world demographics, clinical characteristics, and first-line treatment outcomes in metastatic non-small-cell lung cancer (NSCLC) patients with these mutations.</div></div><div><h3>Methods</h3><div>This retrospective, multi-institution observational study used data from the AURORA database. Patients aged 18 years or older, diagnosed with metastatic <em>KRAS G12D</em> or <em>G12C</em> NSCLC between January 1, 2010, and April 30, 2024, were included. Descriptive statistics compared patient characteristics, and time-to-event outcomes were assessed using Cox proportional hazards regression.</div></div><div><h3>Results</h3><div>A total of 298 (216 <em>KRAS G12C</em> and 82 <em>KRAS G12D</em>) patients were included. The <em>KRAS G12D</em> group had a higher proportion of never smokers (15 % vs. 1 %, p &lt; 0.01) and PD-L1 &lt; 1 % (36 % vs. 21 %, p = 0.06). No significant differences were observed in overall survival (OS) (HR 1.09, 95 % CI 0.80–1.48, p = 0.60) or real-world progression-free survival (rwPFS) (HR 1.21, 95 % CI 0.92–1.59, p = 0.18) between mutation groups. In <em>KRAS G12C</em>, monotherapy immunotherapy (HR 0.61, 95 % CI 0.39–0.97, p = 0.04) and chemo-immunotherapy (HR 0.59, 95 % CI 0.37–0.94, p = 0.03) improved OS compared to chemotherapy. For <em>KRAS G12D</em>, neither immunotherapy (HR 0.74, 95 % CI 0.29–1.89, p = 0.53) nor chemo-immunotherapy (HR 0.73, 95 % CI 0.34–1.57, p = 0.42) improved OS compared to chemotherapy alone.</div></div><div><h3>Conclusion</h3><div><em>KRAS G12C</em> and <em>G12D</em> mutations demonstrate distinct clinical characteristics and treatment responses, with poorer immunotherapy outcomes in <em>KRAS G12D</em> patients. Prospective studies are needed to validate these findings.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108421"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies","authors":"Bokyung Ahn ,&nbsp;Deokhoon Kim ,&nbsp;Wonjun Ji ,&nbsp;Sung-Min Chun ,&nbsp;Goeun Lee ,&nbsp;Se Jin Jang ,&nbsp;Hee Sang Hwang","doi":"10.1016/j.lungcan.2025.108445","DOIUrl":"10.1016/j.lungcan.2025.108445","url":null,"abstract":"<div><h3>Background</h3><div>The clinicopathologic and therapeutic significance of <em>SMARCA4</em> mutation in non-small cell lung carcinoma (NSCLC) remains unclear.</div></div><div><h3>Methods</h3><div>We retrieved 575 NSCLC cases from the clinical target sequencing cohort (N = 2157) to compare the clinicopathologic characteristics of groups subclassified based on the presence of truncated or non-truncated <em>SMARCA4</em> mutations (<em>SMARCA4</em>-truncated, <em>SMARCA4</em>-non-truncated, and <em>SMARCA4</em>-wild type [WT]). The differences in gene expression profiles between these groups were evaluated using the TCGA-LUAD dataset.</div></div><div><h3>Results</h3><div>Fifty (2.3%) <em>SMARCA4</em>-truncated and 63 (2.9%) <em>SMARCA4</em>-non-truncated NSCLCs were identified. The majority of <em>SMARCA4</em>-truncated NSCLCs were present in male smokers (94.0%) and pathologically diagnosed as adenocarcinoma (76.0%). The <em>SMARCA4</em>-truncated group showed rare targetable driver alterations with a higher tumor mutation burden than the <em>SMARCA4</em>-WT group. Gene expression profile analysis revealed that cancer/testis antigen (CTA) expression was enriched in the <em>SMARCA4</em>-truncated group, with up to 57% of the cases displaying immunoreactivities for MAGEA4, CT45A, and/or PRAME. The <em>SMARCA4</em>-non-truncated group showed heterogeneous clinicopathologic, genomic, and immunohistochemical features that fell between <em>SMARCA4</em>-truncated and WT groups. Both <em>SMARCA4</em>-truncated and non-truncated groups showed significantly poor prognosis with pemetrexed-platinum chemotherapy, yet there was no significant difference in survival following immune checkpoint inhibitor monotherapy.</div></div><div><h3>Conclusion</h3><div><em>SMARCA4</em>-truncated NSCLC represents a variant of driver-negative NSCLC, mainly occurring in male smokers with poorly differentiated adenocarcinoma histology. In contrast, <em>SMARCA4</em>-non-truncated NSCLC indicates a heterogeneous subpopulation, exhibiting intermediate characteristics between the <em>SMARCA4</em>-truncated and <em>SMARCA4</em>-WT groups. While showing poor response to pemetrexed-platinum chemotherapy, increased CTA expression could be a novel therapeutic target in <em>SMARCA4</em>-mutated NSCLCs.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108445"},"PeriodicalIF":4.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy","authors":"Lin Huang,&nbsp;René Horsleben Petersen","doi":"10.1016/j.lungcan.2025.108438","DOIUrl":"10.1016/j.lungcan.2025.108438","url":null,"abstract":"<div><h3>Background</h3><div>The choice of surgical procedure for early-stage non-small cell lung cancer (NSCLC) with tumour spread through air spaces (STAS) remain debated. This study aimed to analyse the prognostic influence of STAS on thoracoscopic segmentectomy compared to lobectomy for clinical stage I NSCLC.</div></div><div><h3>Methods</h3><div>This retrospective study included prospectively collected data of consecutive patients who underwent thoracoscopic segmentectomy or lobectomy for clinical stage I NSCLC from September 2020 to September 2023 at a high-volume hospital. We assessed overall survival (OS) and recurrence-free survival (RFS) using Kaplan-Meier estimator with log-rank test. LASSO-Cox and Cox regression analyses identified independent factors for survivals of STAS presence.</div></div><div><h3>Results</h3><div>Among the 785 patients in the study, 151 (19.2 %) had STAS-positive NSCLC. No significant difference was observed in OS and RFS between patients with the presence and absence of STAS, nor between those undergoing thoracoscopic segmentectomy and lobectomy for NSCLC in the absence of STAS. Whereas worse survivals were found in segmentectomy for patients with STAS when compared to lobectomy (3-year OS: 58.4 % vs 89.0 %, P &lt; 0.001; 3-year RFS: 69.8 % vs 82.7 %, P &lt; 0.001). On multivariable analysis, segmentectomy (vs. lobectomy) and increased maximum standardized uptake value in positron emission tomography were independent prognostic factors of OS (hazard ratio [HR] 5.81, P = 0.010; HR 1.12, P = 0.022) and RFS (HR 5.78, P = 0.004; HR 1.10, P = 0.025) among patients with STAS.</div></div><div><h3>Conclusions</h3><div>In this study, segmentectomy for clinical stage I NSCLC with STAS had inferior RFS and OS when compared to lobectomy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108438"},"PeriodicalIF":4.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer","authors":"Joaquim Bosch-Barrera ,&nbsp;Purificación Estévez-García ,&nbsp;Paloma Martín-Martorell ,&nbsp;Renaud Sabatier ,&nbsp;Ernest Nadal ,&nbsp;Elia Sais ,&nbsp;Pere Gascón ,&nbsp;Ana Oaknin ,&nbsp;Jordi Rodon ,&nbsp;Jose M. Lizcano ,&nbsp;Pau Muñoz-Guardiola ,&nbsp;Gemma Fierro-Durán ,&nbsp;Oriol Pedrós-Gámez ,&nbsp;Héctor Pérez-Montoyo ,&nbsp;Marc Yeste-Velasco ,&nbsp;Marc Cortal ,&nbsp;Antonio Pérez-Campos ,&nbsp;José Alfón ,&nbsp;Carles Domènech ,&nbsp;Teresa Morán","doi":"10.1016/j.lungcan.2025.108105","DOIUrl":"10.1016/j.lungcan.2025.108105","url":null,"abstract":"<div><h3>Background</h3><div>Advanced squamous non-small cell lung cancer (sq-NSCLC) has long relied on chemotherapy and, more recently, on its combination with PD-1 immunotherapy. Ibrilatazar (ABTL0812) is an innovative oral agent that induces cytotoxic autophagy selectively in cancer cells. In the ENDOLUNG trial we have evaluated the efficacy and safety of ibrilatazar combined with chemotherapy in sq-NSCLC patients.</div></div><div><h3>Methods</h3><div>Patients with stage III/IV sq-NSCLC received ibrilatazar (1300 mg tid) alongside paclitaxel (175 mg/m2) and carboplatin (AUC 5) every 3 weeks for up to 8 cycles, followed by ibrilatazar maintenance until progression or toxicity. Primary endpoint was overall response rate (ORR) per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>40 patients were enrolled constituting the intention-to-treat (ITT) population (90 % male, median age 66, ECOG 0–1). The efficacy analysis (FA) subset included 25 patients, excluding 15 patients without a measurement of the primary variable. For ITT and FA populations, the ORR was 32.5 % (95 % Confidence Interval (CI) 21.3–50.1) vs 52.0 % (95 % CI 34.2–65.9), the disease control rate (DCR) was 52.5 % (95 % CI: 36.1–68.5) vs 84.0 % (95 % CI: 63.9–95.5), the PFS was identical (6.2 months; 95 % CI: 4.4–8.8) and the OS was 18.4 months (95 % CI: 9.5-NC) and 22.5 months (95 % CI: 10.4-NC), respectively. Most common adverse events included asthenia (62.5 %), diarrhea (45.0 %), nausea (37.5 %), anemia (32.5 %) and neutropenia (27.5 %). Pharmacokinetic and pharmacodynamic data confirmed ibrilatazar activity.</div></div><div><h3>Conclusions</h3><div>Ibrilatazar combined with paclitaxel and carboplatin shows promising efficacy and safety in sq-NSCLC, warranting further clinical development.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108105"},"PeriodicalIF":4.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}